Effects of prostate cancer screening on health-related quality of life: Results of the Finnish arm of the European randomized screening trial (ERSPC)

Vasarainen, Hanna; Malmi, Hanna; Määttänen, Liisa; Ruutu, Mirja; Tammela, Teuvo L.J.; Taari, Kimmo; Rannikko, Antti; Auvinen, Anssi

doi:10.3109/0284186x.2013.802837

Cited by 23 publications

(17 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ERSPC participants without prostate cancer reported good urinary and bowel function, low bother (EPIC score) and reduced sexual function, which worsened in older men (Dutch questionnaire) in a similar manner to randomized participants in the ProtecT trial. There were few changes in quality of life and anxiety during ERSPC screening and their SF‐36 scores were consistent with the ProtecT trial SF‐12 scores at PSA testing and biopsy (scoring equivalency exists between questionnaires ). Men with high levels of anxiety during ERSPC screening were predicted to have high anxiety at recruitment , which was also observed in the wider ProtecT trial cohort .…”

Section: Discussionsupporting

confidence: 69%

Patient‐reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and quality of life

et al. 2016

View full text Add to dashboard Cite

ObjectivesTo present the baseline patient‐reported outcome measures (PROMs) in the Prostate Testing for Cancer and Treatment (ProtecT) randomized trial comparing active monitoring, radical prostatectomy and external‐beam conformal radiotherapy for localized prostate cancer and to compare results with other populations.Materials and MethodsA total of 1643 randomized men, aged 50–69 years and diagnosed with clinically localized disease identified by prostate‐specific antigen (PSA) testing, in nine UK cities in the period 1999–2009 were included. Validated PROMs for disease‐specific (urinary, bowel and sexual function) and condition‐specific impact on quality of life (Expanded Prostate Index Composite [EPIC], 2005 onwards; International Consultation on Incontinence Questionnaire‐Urinary Incontinence [ICIQ‐UI], 2001 onwards; the International Continence Society short‐form male survey [ICSmaleSF]; anxiety and depression (Hospital Anxiety and Depression Scale [HADS]), generic mental and physical health (12‐item short‐form health survey [SF‐12]; EuroQol quality‐of‐life survey, the EQ‐5D‐3L) were assessed at prostate biopsy clinics before randomization. Descriptive statistics are presented by treatment allocation and by men's age at biopsy and PSA testing time points for selected measures.ResultsA total of 1438 participants completed biopsy questionnaires (88%) and 77–88% of these were analysed for individual PROMs. Fewer than 1% of participants were using pads daily (5/754). Storage lower urinary tract symptoms were frequent (e.g. nocturia 22%, 312/1423). Bowel symptoms were rare, except for loose stools (16%, 118/754). One third of participants reported erectile dysfunction (241/735) and for 16% (118/731) this was a moderate or large problem. Depression was infrequent (80/1399, 6%) but 20% of participants (278/1403) reported anxiety. Sexual function and bother were markedly worse in older men (65–70 years), whilst urinary bother and physical health were somewhat worse than in younger men (49–54 years, all P < 0.001). Bowel health, urinary function and depression were unaltered by age, whilst mental health and anxiety were better in older men (P < 0.001). Only minor differences existed in mental or physical health, anxiety and depression between PSA testing and biopsy assessments.ConclusionThe ProtecT trial baseline PROMs response rates were high. Symptom frequencies and generic quality of life were similar to those observed in populations screened for prostate cancer and control subjects without cancer.

show abstract

Section: Discussionsupporting

confidence: 69%

Patient‐reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and quality of life

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Each subscale with higher scores indicates better corresponding HRQOL domain (Ware & Sherbourne, ). The RAND‐36 is an internationally used instrument in measuring the HRQOL of patients with prostate cancer and their spouses (Cary et al, ; Dieperink et al, ; Harden et al, ; Treiyer, Anheuser, Butow, & Steffens, ; Vasarainen et al, ). In international surveys on patients with prostate cancer, the coefficients have been over 0.88 (Harden et al, , ).…”

Section: Methodsmentioning

confidence: 99%

“…Combined treatments and use of medication have been associated with worse physical and role functioning among patients with prostate cancer (Green, Wells, & Laakso, ). Ratings for physical and social functioning are the highest among the subscales for HRQOL before treatment (Green et al, ; Paterson, Robertson, Smith, & Nabi, ; Vasarainen et al, ), while global quality of life/general health and vitality are the weakest subscales (Cary, Singla, Cowan, Carroll, & Cooperberg, ; Green et al, ; Vasarainen et al, ). Three months following the prostate cancer treatment, patients reported that physical functioning, energy, and general health were lower when compared to other items on a generic HRQOL scale.…”

Section: Introductionmentioning

confidence: 99%

The health‐related quality of life of patients with prostate cancer and their spouses before treatment compared with the general population

Harju

Rantanen

Kaunonen

et al. 2017

Int J of Nursing Practice

View full text Add to dashboard Cite

show abstract

“…The wide adoption of PSA screening has been proved to increase diagnosis, to induce over treatment, to cause anxiety, treatment adverse events and to reduce the quality of life of patients [20,21]. For these reasons continuous efforts are made to identify new more reliable markers for the diagnosis and prognosis of PCa other than PSA.…”

Section: Discussionmentioning

confidence: 99%

DKK-1 in prostate cancer diagnosis and follow up

et al. 2014

View full text Add to dashboard Cite

BackgroundDickoppf-1 (DKK-1) is a negative regulator of bone formation with tumorigenic potential. The up-regulation of DKK-1 is an early event in prostate cancer (PCa) development, thus we investigated its role as a marker in the diagnosis and prognosis of PCa.MethodsWe retrospectively enrolled 159 patients who underwent prostate biopsy, either for elevated PSA or suspect digital rectal examination, between 2003 and 2010. During the biopsy, one serum sample was collected from all patients; PSA and DKK-1 were measured by ELISA technique. Amongst the biopsy of 159 patients 75 were affected by PCa and 84 were not the mean period of follow-up for these patients was 5 years; a new biopsy was performed in case of PCa suspicion.ResultsPSA performed better than DKK-1 in detecting PCa (0.63 vs 0.51 respectively). Differently from PSA DKK-1 was significantly higher in patients who developed PCa during follow-up than in cancer-free ones, thus DKK-1 performed better than PSA in detecting these patients (0.67 vs 0.55). DKK-1 was significantly lower in patients with bone metastases, whereas PSA was not significantly different in patients with different outcomes.ConclusionsDKK-1 might be predictive for patients negative at first biopsy who will develop PCa and in the prognosis of bone metastases. It performed worse than PSA in the early diagnosis of Pca.

show abstract

Effects of prostate cancer screening on health-related quality of life: Results of the Finnish arm of the European randomized screening trial (ERSPC)

Cited by 23 publications

References 23 publications

Patient‐reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and quality of life

Patient‐reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and quality of life

The health‐related quality of life of patients with prostate cancer and their spouses before treatment compared with the general population

DKK-1 in prostate cancer diagnosis and follow up

Contact Info

Product

Resources

About